Another downgrade; is this the darkest before the dawn?
05/11/25 -"The Q3 results missed expectations, as Novo contended with competition from compounding pharmacies and Eli Lilly. Moreover, the management again downgraded its 2025 outlook. The ongoing bidding war ..."
Pages
78
Language
English
Published on
05/11/25
You may also be interested by these reports :
05/11/25
The Q3 results missed expectations, as Novo contended with competition from compounding pharmacies and Eli Lilly. Moreover, the management again ...
04/11/25
The Q3 operating profitability exceeded expectations, though sales fell short of consensus. The management reaffirmed its full-year guidance. While ...
03/11/25
BioNTech reported mixed Q3 results. Sales significantly exceeded market expectations, but the operating loss was higher than anticipated. The 2025 ...
31/10/25
Novo has locked horns with Pfizer by proposing to acquire obesity-focused Metsera, after Pfizer had made an offer in September 2025. Metsera’s ...